<DOC>
	<DOCNO>NCT02895412</DOCNO>
	<brief_summary>This study test new therapy patient acute myeloid leukaemia undergo blood stem cell transplant . In study , investigator take small number immune cell whose normal function give immunity infection help fight leukaemia . These cell stimulate multiply laboratory give transplant recipient transplant . This sort `` immunity transplant '' . The exact purpose study investigate cell safe effective patient transplant AML .</brief_summary>
	<brief_title>Infection Tumour Antigen Cellular Therapy</brief_title>
	<detailed_description>The study analyse safety biological efficacy administer investigational product ( donor-derived Wilm 's Tumour Antigen-specific cytotoxic T lymphocytes cytotoxic T lymphocytes specific multiple opportunistic pathogen ( cytomegalovirus ( CMV ) , Adenovirus ( Adv ) , Epstein Barr virus ( EBV ) , Varicella-Zoster virus ( VZV ) , Influenza , BK virus ( BKV ) , fungal infection ) , hereafter refer P-CTLs ) prophylaxis relapse , viral fungal reactivation infection follow allogeneic blood marrow transplantation acute myeloid leukaemia . P-CTL give prophylactically minimum 28 day transplantation follow administration monthly infusion WT1-CTL four dos . Our aim study safety combine WT1-CTL P-CTL infusion ; persistence , effect relapse disease , effect minimal residual disease , reconstitution WT-1 pathogen-specific immunity , viral reactivation , infection rate transplantation , viral load ; use antiviral antifungal pharmacotherapy specific infection , hospitalisation overall survival . Safety infusion respect development adverse event within first 12 month post-transplant assess .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Patients undergo myeloablative nonmyeloablative allogeneic transplantation HLA ( A , B DR ) identical 13 antigen mismatch family unrelated donor 2 . Transplant perform acute myeloid leukaemia 3 . Leukaemia blast express WT1 tumour antigen determine European LeukaemiaNet standardise assay describe 16 . WT1 overexpression define great 250 copies/104ABL copy bone marrow sample great 50 copies/104ABL copy peripheral blood . This assay perform sample collect part routine clinical care diagnosis initial treatment prior transplantation . Testing performed consent trial participation obtain negativity WT1 classify screening failure 4 . Recipients peripheral blood HSCT 5 . Adequate hepatic renal function ( &lt; 3 x upper limit normal AST , ALT , &lt; 2 x upper limit normal total bilirubin , serum creatinine ) 6 . Estimated life expectancy least 12 month 7 . Patient ( legal representative ) give informed consent 1 . Use antilymphocyte globulin ( ALG , ATG , Campath broad spectrum lymphocyte antibody ) give 4 week immediately prior infusion plan within 4 week infusion 2 . Grade II great graft versus host disease within 1 week prior infusion 3 . Prednisone methylprednisone dose &gt; 1 mg/kg ( equivalent steroid preparation ) administer within 72 hour prior cell infusion 4 . Prior allogeneic HSCT 5 . Privately insured outpatient ( see Indemnity Issues , Section 11.4 )</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>